ZEO ScientifiX Announces Major Strategic Collaboration Expanding Longevity & Regenerative Medicine Reach
ZEO ScientifiX Announces Major Strategic Collaboration Expanding Longevity & Regenerative Medicine Reach
Key Highlights from the Announcement
-
ZEO ScientifiX, Inc. (OTCQB: ZEOX) has entered into a memorandum of understanding (MOU) with Regen Therapy to become the exclusive core supplier of advanced biologics for Regen’s next-generation regenerative medicine platform.
-
A strategic partnership between Regen Therapy and Stealth Health will deliver scalable, white-label telemedicine and longevity services to a network of over 3,000 clinics and 24,000 practitioners across the U.S.
-
The collaboration integrates Stealth Health’s licensed prescriber network, pharmacy fulfillment infrastructure, and telemedicine platform, enabling clinics to offer specialized, physician-guided longevity and regenerative therapies under their own brands.
-
ZEO ScientifiX will be the exclusive partner for biologic research, development, and manufacturing, providing advanced biologic therapeutics—including expertise in extracellular vesicle biology and perinatal-derived therapies—for Regen’s growing clinical platform.
-
The partnership leverages the Metabolic Code® precision health platform, enabling data-driven, personalized health assessments and care plans across the expansive clinic network.
Investor-Focused Details: What Shareholders Need to Know
-
Major Commercial Expansion: ZEO ScientifiX is positioned to supply therapeutics to a fast-growing, nationwide clinic network—potentially accelerating product adoption, revenue growth, and market footprint in the U.S. regenerative medicine sector.
-
Vertically Integrated Ecosystem: The partnership creates a turnkey solution for clinics, combining clinical delivery, telemedicine infrastructure, and cutting-edge biologic product development. This could drive rapid scaling and reduce operational barriers for clinic adoption.
-
Industry Validation & Potential for Market Leadership: ZEO’s selection as core supplier by Regen Therapy validates its scientific and manufacturing capabilities and could position ZEO as a central player in the U.S. longevity and regenerative medicine market.
-
Scalable, Data-Driven Longevity Programs: With the integration of Metabolic Code®’s Bayesian model (which analyzes 40,000 data points per assessment), clinics can deliver precision, patient-specific longevity care—potentially setting a new standard in the industry.
-
Large, Addressable Market: The global longevity market is projected to exceed \$93 billion by 2027. ZEO’s entry into this space through Regen’s network could represent a significant revenue and growth opportunity.
-
Regulatory & Operational Advantages: The white-label, fully managed approach removes key regulatory and operational hurdles for clinics, further supporting rapid nationwide adoption and high clinical compliance.
-
Potential Share Price Sensitivity: The scale of the partnership, ZEO’s central supplier position, and the company’s opportunity to play a key role in a rapidly expanding market could positively influence investor sentiment and ZEOX share price, especially as commercial milestones are met and clinic adoption accelerates.
Strategic and Scientific Details
-
Stealth Health Platform: Offers clinics a HIPAA-compliant, white-label MSO platform, licensed prescriber network, direct-to-patient telehealth, and pharmacy fulfillment—all delivered under the clinic’s brand.
-
Metabolic Code®: Founded by renowned clinical pharmacist Jim LaValle, the platform delivers individualized health assessments and care plans by identifying imbalances across five key physiological networks (TRIADS™). It is already adopted by leading organizations, including LIFE TIME.
-
Biologic Innovation: ZEO’s expertise in extracellular vesicle biology, perinatal-derived therapeutics, and acellular signaling technologies will underpin Regen’s next-generation regenerative products. All therapeutics will be produced through cGMP-compliant manufacturing processes, ensuring high quality and regulatory adherence.
-
Clinical Leadership: The initiative is led by recognized industry figures including Matthew Mazzuca (Stealth Health CEO), James LaValle (Metabolic Code Founder), George C. Shapiro, MD, FACC (ZEO CMO), and Sanjiv Lal (Regen Therapy partner).
-
Immediate Impact: Clinics in Regen’s ecosystem can immediately access new services such as hormone replacement therapy, GLP-1 weight management, peptide therapeutics, and broader longevity protocols without investing in new in-house infrastructure.
-
Market Timing: The collaboration comes as demand for personalized, proactive health solutions is rapidly rising, but most clinics lack access to specialized prescribers, integrated pharmacy networks, and advanced technology.
About the Companies
-
ZEO ScientifiX (OTCQB: ZEOX): A clinical-stage biopharmaceutical company specializing in the development and cGMP-compliant manufacturing of advanced biologic therapeutics for regenerative medicine and human performance.
-
Regen Therapy: A clinical education and consulting platform for healthcare providers and longevity clinics, supporting over 3,000 clinics with operational, research, and education services.
-
Stealth Health: A Texas-based telemedicine and longevity medicine company offering a white-label MSO platform, prescriber network, and pharmacy fulfillment built on a HIPAA-compliant technology stack.
-
Metabolic Code®: A cloud-based, precision health platform leveraging advanced analytics to deliver personalized, ongoing metabolic optimization and care plans.
Contact Information
Disclaimer: This article contains forward-looking statements, including statements about potential market impact, revenue growth, and strategic advantages for ZEO ScientifiX and its partners. Actual results may differ due to risks and uncertainties inherent in clinical-stage biotechnology, regulatory approval, market acceptance, and operational execution. Investors should conduct their own due diligence and consider all relevant risks before making investment decisions. This article is for informational purposes only and does not constitute investment advice.
View Zeo ScientifiX, Inc. Historical chart here
